# Vistagen Therapeutics

Vistagen Therapeutics is an Asset Manager based in South San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** South San Francisco, United States
- **Region:** North America
- **Address:** South San Francisco, CA, United States
- **Founded:** 1998
- **Assets under management:** Undisclosed
- **Website:** vistagen.com

## Regulatory record

- **Reports private funds:** No

## About

Vistagen was founded in 1998 but materially reshaped its identity upon Singh's leadership, focusing exclusively on neuroscience. The firm does not manage outside capital; it is a publicly traded development-stage company that advances its own drug candidates through the FDA process, funded by periodic public equity offerings. The platform is built around pherines, a proprietary class of nasal chemosensory molecules designed to regulate neural circuits without systemic absorption or benzodiazepine-like side effects. Lead candidate fasedienol (PH94B) is in Phase 3 for social anxiety disorder, with earlier-stage programs targeting major depressive disorder and vasomotor symptoms. Development is entirely U.S.-based, with clinical trial sites concentrated in North America. The company reported a workforce of approximately 40 full-time employees per its 2024 10-K filing, with R&D activities outsourced to contract research organizations. No adjacent vehicles or philanthropic structures are reported. In May 2024, Vistagen announced positive topline results from a Phase 3 trial of fasedienol, sending its stock sharply higher and marking its most significant clinical milestone to date. Vistagen's structural difference from a traditional asset manager or family office is fundamental: it is a single-pipeline public biotech, which means its "allocation" is binary—every dollar raised goes into advancing its own drugs toward regulatory approval, offering no diversification across sectors or strategies. Succession risk and governance are tied entirely to the board and CEO, not to a family or founder liquidity event.

## Sectors

- Digital Health
- Healthcare Services

## People

- Shawn Singh — Chief Executive Officer

## Questions

### Who runs investment decisions at Vistagen Therapeutics?

Vistagen is not an investment firm. It is a publicly traded clinical-stage biotech company. Capital-allocation decisions are made by CEO Shawn Singh and the board of directors, and are limited to funding the company's own neuroscience drug pipeline through periodic public equity raises.

### How is Vistagen's drug-development strategy different from traditional psychiatric medications?

Vistagen's pipeline relies on pherines, a proprietary class of nasal-spray chemosensory molecules. Unlike traditional oral antidepressants or benzodiazepines, pherines are designed to act on peripheral nasal receptors to modulate brain function without systemic uptake, aiming for rapid-onset efficacy with a lower side-effect burden.

## Related profiles

- [Serina Therapeutics](https://altss.com/profile/serina-therapeutics-inc)
- [GEE Group](https://altss.com/profile/gee-group-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/vistagen-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology